Вісник проблем біології і медицини -2023 -Вип. 2 (169) / Bulletin of problems in biology and medicine -2023 -Issue 2 (169) 215 КЛІНІЧНА ТА ЕКСПЕРИМЕНТАЛЬНА МЕДИЦИНА / CLINICAL AND EXPERIMENTAL MEDICINE diagnosis of AH was set according to the recommendations of the International Society of Hypertension (ISH), 2020.The diagnosis of T2DM and obesity was based on clinical, instrumental, and biochemical criteria according to the recommendations of WHO experts and the European Society of Endocrinology. A comparative analysis of the use of different treatment regimens for patients with hypertension, concomitant type 2 diabetes and obesity using the angiotensin-converting enzyme inhibitor ramipril and the angiotensin II receptor blocker telmisartan was conducted.Results. It was found that following antihypertensive treatment for three months, the levels of systolic blood pressure (SBP) (by 19.6%), diastolic blood pressure (DBP) (by 15%), and heart rate (HR) (by 9%) decreased significantly. As for echocardiographic characteristics, the following levels decreased: EDV by 25.5%, ESV by 17.3%, EDD by 24.0%, LVMM by 8.3%; EF increased by 6% compared to the pretreatment values.Conclusions. Treatment of arterial hypertension in patients with type 2 diabetes mellitus and obesity with ramipril or telmisartan as standard therapy has demonstrated a positive effect on the structural and functional parameters of the left ventricle and ejection fraction, which may subsequently prevent the development and progression of vascular complications.

No abstract